Patients undergoing chemotherapy for cancer.

How many children worldwide have been orphaned by the death of their father due to cancer?

This is one of the pressing questions researchers will aim to answer and that is a topic amongst the abstracts at this month’s World Cancer Congress. The study, conducted by the France-based International Agency for Research on Cancer (IARC), builds on a previous 2022 report revealing that one million children lose their mother to cancer each year. According to the research team, these children often feel trapped in a “vicious cycle of disadvantage.”

The World Cancer Congress will occur from September 17-19 in Geneva. Some 2,000 people from around 100 countries are expected to take part. Attendees will hear from Malaysian Health Minister HE Datuk Seri Dr Dzulkefly bin Ahmad; Olivier Michielin, chairperson of the Department of Oncology, Geneva University Hospitals; Pierre Maudet, Geneva State Counsellor in charge of Health; and many more related leaders. The event is a project of the Union for International Cancer Control (UICC), the largest and oldest – founded in 1933 – international cancer organisation. Today, UICC has over 1,100 member organisations in 170 countries and territories.

The event will focus on six themes: Prevention, screening and early detection; cancer research and progress; healthcare systems and policies; cancer treatment and palliative care; tobacco control; and people living with cancer

“I think the highlights of any congress are the plenaries because that’s when everyone attending the congress gathers in the same room to discuss and listen to a subject matter that is critically important to the community,” Cary Adams, CEO of UICC, told Health Policy Watch. “This year’s plenaries cover global advocacy, which will lead to the high-level meeting on non-communicable diseases next year; the challenges of women and cancer, and the differences between cancer affecting women and men, and what can be done to ensure that gender differences are appreciated country by country; and the third plenary on the real-world applications of new technologies like AI, which are important to the global cancer community. I always look forward to the plenaries because I know the subject matters are pertinent and relevant to all.”

In Dwazark Community, Freetown, Sierra Leone, students at St. Augustine School are receiving the HPV vaccine to protect against cervical cancer.

HOW CANCER DEATHS COULD BE AVOIDED

Equity in cancer care will play a big role in this year’s event, said Eric Grant, communications and media manager for UICC. He told Health Policy Watch that participants will look at ways to ensure that there is access to care regardless of gender or geography, amongst other factors.

A related, first-of-its-kind study will debut at the congress that quantifies the socioeconomic burden of ovarian cancer across 11 countries and highlights the significant disparities between countries and income groups.

Relatedly, there will be a session on cancer care during humanitarian crises, drawing on experiences from Sudan, Gaza, and Haiti.

UN Headquarters in Geneva: Participant in 43rd Session of the UN Human Rights Council dons mask to protect herself from COVID-19. All parallel sessions and side events have been cancelled.

WHY GENEVA?

According to CEO Adams, the World Cancer Congress is being held in Geneva for the second time since 2022, a decision originally influenced by the COVID-19 pandemic.

“We normally take the congress around the world, but given the pandemic, we felt it was inappropriate to go to a location where it was unclear what the COVID situation would be,” Adams explained. “We spoke to the Geneva Government and various organisations that support international events here and received a very positive response. So, in 2022, we decided to hold the Congress in Geneva.

“The board then decided, as a result of how successful that meeting was and given the ongoing challenges of the pandemic, that although tradition says that we take the congress around the world, there would be real value and benefits in running it a second time in Geneva,” he continued. “I must say that given that the first congress in 2022 ran so well and everyone enjoyed being in the hub of global Health, meeting organisations like the World Health Organisation, the Medicines Patent Pool, FIND, and individuals from other UN agencies in Geneva, it was an experience that could be repeated and would be appreciated just as much the second time around. So that’s why we’re in Geneva for a second year.”

This year’s congress will once again have a focus on COVID-19, including the release of an IARC assessment on the pandemic’s impact on cancer diagnosis and stage distribution based on data from population-based cancer registries in seven countries.

Ad for tobacco

TOBACCO ADVERTISING REMAINS ‘SIGNIFICANT’ OBSTACLE

When it comes to the causes of cancer, multiple sessions will deal with the impact of commercial determinants on Health, such as the influence of tobacco and alcohol on cancer.

Grant highlighted that tobacco advertising remains a significant obstacle to reducing tobacco use. One session will equip attendees with skills to monitor, document, and expose the tactics used by the tobacco industry.

A new study on tobacco advertising on social media in Germany will be presented. Another study will examine how the “no safe level” message regarding alcohol consumption relates to cancer risk.

The use of artificial intelligence and other new technologies in healthcare to transform patient care and enhance diagnostics and treatments will also be explored—both from the standpoint of the advancements they can provide and challenges like data privacy.

PATIENTS WILL BE PRESENT

Grant told Health Policy Watch that about 40% of UICC’s members are members of patient groups, meaning they had cancer themselves. They will have a strong presence at the congress. Mobilising their voices can help encourage policymakers to move legislation forward to support cancer diagnosis, treatments and patients, Grant said.

“We’re fortunate at the World Cancer Congress in that we appeal to not just oncologists, added Adams. “There is a tendency for people to think that a cancer congress will be attended only by oncologists, but this is not true for the World Cancer Congress. We have organisations attending, such as patient groups, cancer societies, cancer leagues, research institutes, and cancer hospitals. They come from a range of disciplines—from tobacco control specialists to palliative care specialists, advocates, and fundraisers—and we get a wide variety of ages and a really diverse population of people, but with a common ambition to improve cancer control in their country, whether that’s improving prevention, early detection, treatment, care, or supportive care.

“That is a unique aspect of this congress.”

This article is part of a Health Policy Watch-UICC media partnership, with no financial compensation involved.

To register for the congress, visit https://www.worldcancercongress.org.

Image Credits: National Cancer Institute, Roche, Gavi, UN Photo / Jean Marc Ferré, Standford School of Medicine .

While more countries are concerned about antimicrobial resistance (AMR) than a decade ago, many are reluctant to commit to a specific target to reduce the overuse of animal antibiotics as they negotiate a political declaration ahead of the United Nations high-level meeting on AMR.

The zero draft of the declaration issued on 20 May proposed a target of “at least 30%” reduction in “the quantity of antimicrobials used in the agri-food system globally” by 2030.

But “a lot of countries still seem keen to water down very concrete commitments on things like reducing animal use of antibiotics”, Jeremy Knox, head of infectious disease policy at Wellcome Trust, told a media briefing on Monday.

However, Knox said he was “cautiously optimistic” about the outcomes of the UN high-level meeting set for 26 September – eight years after the only other HLM on the issue in 2016.

Wellcome has proposed three key strategies to address AMR  – a political “rallying cry” (such as the climate sector’s target of no more than a 2ºC temperature increase), a global scientific evidence panel on AMR, and sustained political follow-up, said Knox.

“I don’t think we’ll end up with the kind of very clear and ambitious rallying cry that we might have hoped for, but I do think we will see some commitments which are steps in the right direction,” said Knox.

“We will most likely have something like an ambition for a 10% reduction in mortality [on the 2019 baseline figure of 1.27 million annual deaths] but that’s narrower and less ambitious than some of us might have hoped for.”

Wellcome head of infectious disease policy Jeremy Knox

Investors call for action

The Investor Action on AMR (IAAMR) initiative, supported by 80 investors who represent $13 trillion in assets, issued a call on Tuesday for global policymakers to take “critical action against the escalating AMR crisis”.

AMR claimed 1.27 million lives in 2019, surpassing deaths from HIV and malaria, with this figure set to rise to 10 million annually by 2050.

“With the global economic costs associated with AMR likely to reach $100 trillion and lead to a 3.8% decrease in global GDP by 2050, the investor community is increasingly concerned with the negative impact AMR will have on global financial markets, economic stability and long-term value generation,” said IAAMR in a statement. 

IAAMR was founded by the Access to Medicine Foundation, the $75 trillion FAIRR investor network and the UK Department of Health and Social Care,

“Companies – from pharma to pork producers – take advantage of lax regulations allowing the routine use of antibiotics in animals enabling them to cut corners in animal welfare, while diminishing antibiotic effectiveness in humans,” said Jeremy Coller, Founder and Chair, of FAIRR, which works on building a more sustainable and equitable food system.

“An estimated 80% of antibiotics are administered to livestock rather than people in the United States alone. Investors recognise that AMR is not only a threat to the health of our people and planet, but to the financial well-being of those who rely on investment returns to fund their retirements.” 

IAAMR has seven proposals, three of which dovetail with Wellcome’s three strategies. Like Wellcome, they want a “rallying” aim, political will and an independent global scientific panel on AMR along the lines of the Intergovernmental Panel on Climate Change (IPCC).

This proposal has the support of the governments of the UK and Saudi Arabia, according to IAAMR.

‘Crisis of innovation, talent and market’

There is a “crisis of innovation” in the development of new antibiotics, says Damiano de Felice, chief of external affairs at CARB-X, a public-private partnership that supports the development of new antibiotics.

Even the AMR Action Fund, which was given $1 billion from big pharmaceutical companies, the European Investment Bank and Wellcome, “struggled to find investment opportunities in clinical development exactly because the pipeline is insufficient”, he added.

In the early stages of development, there is a lot of innovation – but most of the product developers are vulnerable because they “tend to be very small”, often coming from academia.

“The few companies that have been scientifically successful in bringing a new product to the market, have done very poorly financially,” he told the Wellcome media briefing.

“At least seven of the small biotech companies that brought a new antibiotic on the market in the past five to 10 years all had significant financial problems, and most of them actually went bankrupt.”

De Felice describes the market conditions for new antibiotics as “broken”. Large pharma companies are not that interested in antibiotics as they are short courses, face competition from generics – and clinicians tend not to prescribe them “to prevent the development of resistance”.

This lack of investment and interest also means that researchers don’t stay in antibiotic R&D – resulting in a “crisis of talent”.

But, says de Felice, there are “push” and “pull” incentives to address these problems. Push incentives provide financial, technical and business support to developers for R&D. Meanwhile, 

A pull incentive meanwhile rewards a new antibiotic which has already been brought to the market, and at least $300 million a year for 10 years should be available for this, he estimates.

‘Best time for bugs’

Anand Anandjumar, co-founder and CEO of Bugworks

Anand Anandjumar, co-founder and CEO of Bugworks, a small biotech company based in Bangalore, wants the UN political declaration on AMR to include a commitment to support innovation.

“We are looking at a long, dark, dangerous battle, so at least setting some very basic goals like five new antimicrobials by 2030 – that gives us about six years to work with – would be good,” said Anandjumar, whose company gets support from CARB-X.

“The bugs that we are seeing today, which are resistant to most antibiotics, are not going to wait for humanity to figure out solutions in our own timelines,” Anandjumar told the Wellcome briefing.

“If you’re a bacteria, there’s no better time than today,” he added. “You have heavy abuse of antibiotics on the one side. Therefore the bacteria are becoming much smarter and are developing mutations and other skills to avoid it. 

“On the other side, you have no R& D because the big pharmaceutical companies don’t find this exciting.”

India has one of the “toughest problems with AMR because of the easy availability of antibiotics and population density, he added,

“It’s a great honour to work on creating a new class of antibiotics from India, because the worst bugs are here.”

He added that AMR was being exacerbated by climate change and war: “Rising temperatures are making bugs much more pathogenic and virulent”, while the wars in Ukraine and Gaza are creating conditions for “superbugs”.

A health facility in DRC’s Maniema receives donated health supplies to address an mpox outbreak in June 2022, but the country has yet to get a single mpox vaccine.

While the Democratic Republic of the Congo (DRC), the epicentre of mpox, has yet to get a single vaccine dose despite battling large outbreaks since 2022, a flurry of activity last week aims to finally change this.

Last Friday, UNICEF announced it had issued an emergency tender for the procurement of mpox vaccines.

Usually, the World Health Organization (WHO) has to issue an emergency use listing (EUL) or full approval before UNICEF or the vaccine alliance, Gavi, can procure vaccines.

But WHO Director-General Dr Tedros Adhanom Ghebreyesus clarified at a media briefing last Friday that the global body has given UNICEF and Gavi authorisation to waive the usual procedure to speed up the procurement of the vaccines.

The emergency tender allows UNICEF to set up conditional supply agreements with vaccine manufacturers that will enable it “to purchase and ship vaccines without delay once countries and partners have secured financing, confirmed demand and readiness, and the regulatory requirements for accepting the vaccines are in place”, said UNICEF.  

UNICEF is also coordinating vaccine donations with the vaccine platform, Gavi, the Africa Centre for Disease Control and Prevention (Africa CDC), WHO and Pan American Health Organization (PAHO).

Derrick Sim, Gavi’s interim chief vaccine programmes officer, said that the tender enables “UNICEF to purchase and deliver vaccines after Gavi and other partners make funding available and sign purchase or donation agreements with manufacturers for the most immediate dose needs”.

“Securing access to supply and financing, delivering doses, and in parallel ensuring countries are ready to administer them, are all vital actions that need to be conducted rapidly but thoroughly, and in a coordinated manner. We welcome this tender as another positive step our alliance and Africa CDC are taking in this response,” added Sims.

Meanwhile, Africa CDC Director General Dr Jean Kaseya said he expects the DRC to start receiving donated vaccines from the US and EU this week.

No approval for mpox vaccines

The WHO decision on EULs for the two vaccines – Bavarian Nordic’s Jynneous (also called MVA-BN) and the Japanese company KM Biologics’ LC16 – is expected in mid-September. As they are already authorised in the European Union and USA, this is expected to be straight forward. 

The DRC issued emergency use approval for the vaccines in late June, but some other African countries with mpox outbreaks – including Burundi, Rwanda, Uganda and Kenya –  have yet to do so.

This will make their access more difficult and once again underscores how useful and important the African Medicines Agency (AMA), currently in the process of being set up, will be in health emergencies. 

Over 18,000 suspected mpox cases, including 629 deaths, have been reported in the DRC so far this year. Four out of five deaths have been in children.

A health worker examines skin lesions that are characteristic of mpox on a child at an mpox treatment
centre near Goma in DRC, on 14 August 2024.

‘Scramble for funds’

The WHO estimates that $135 million is needed to address mpox. Currently, each mpox vaccine costs $100.

Helen Clark, former co-chair of the Independent Panel for Pandemic Preparedness and Response, called on Gavi and other donors to see whether they can use some $1.8 billion left in the COVID-19 vaccine platform, COVAX, for vaccine access for the mpox response. 

“This current scramble for funds is a major reason why The Independent Panel recommended the establishment of an emergency surge finance mechanism – a recommendation which is highly relevant right now,” said Clark in a statement issued on behalf of all active members of the Independent Panel.

“The most urgent focus and investment on the ground must be on rolling out and intensifying basic public health measures,” added Clark.

Focus on public health measures

“It is clear that existing diagnostics cannot be immediately scaled, the vaccines available are insufficient in number and will take time to deploy, and there currently is no proven treatment. 

The spread and harm of mpox can and must be reduced by public health measures that are tailored to the affected communities and to the transmission patterns of the local outbreak. This includes support to health facilities and health workers, and investment in community risk communication and engagement to ensure people understand the risks of both zoonotic infection and human-to-human transmission.”

Over the weekend, over 75 organisations under the Pandemic Action Network sent a letter to the G20 Health Working Group meeting currently underway, urging them to prioritise “the immediate need for resources, including vaccines, to address the mpox outbreak”. 

“The G20 must honour its commitment to prioritising prevention, preparedness, and response to pandemics, including boosting local and regional production of medicines, vaccines, and strategic health supplies,” the letter added.

Image Credits: Eugene Kabambi/ WHO, Guerchom Ndebo/ WHO.

A woman addicted to opium hides her face at a treatment centre in Mazar-i-Sharif.

KABUL, Afghanistan — On Kabul’s eastern outskirts, far from the bustling city centre, lies what locals call “the camp of addicts.” The Avicenna Drug Treatment Center, a massive compound enclosed by towering concrete walls, looms over the Afghan capital.

Within its gates, Afghans face forced rehabilitation in the Taliban’s escalating war on drug addiction, a nationwide crackdown that has intensified since the Islamist militant group reclaimed power in 2021. Nearly 10% of Afghanistan’s population — an estimated four million people — struggle with addiction.

“I was addicted to heroin for 10 years,” said Ehsanullah, a pale man in his late 40s, his voice quivering. “Two months ago, they brought me here to quit drugs. They beat me and warned me not to relapse.”

The Taliban’s methods are often violent. Drug users are forcibly detained using whips and guns, then held for at least 45 days. Their heads are shaved, and they are given inmates’ uniforms.

Overcrowding has forced many drug users into the same prisons that once held Taliban fighters under the previous government’s rule.

Modern drug treatments are virtually non-existent. Medicines like methadone, crucial for managing opioid withdrawal symptoms, are scarce.  International aid, which once supported this treatment, has evaporated since the Taliban’s return to power three years ago.

Ehsanullah’s younger brother, who has witnessed his sibling’s ongoing battle with opioid addiction, said the Taliban’s brutal methods are not working.

“Whenever he gets a chance to escape and return to addiction, he does, because he feels alienated, insecure and stressed in normal settings in society,” he said, adding that the Taliban’s methods are not backed by medical evidence.

Health experts agree. Maiwand Hoshmand, a psychologist at Kabul’s Avicenna Hospital, emphasized the complex nature of addiction, noting that family problems and mental disorders play a major role in Afghanistan’s addiction crisis.

“Forty-five days is considered a standard period for quitting addiction, but for patients who have mental problems, the process of leaving them continues for 90 days,” Hoshmand said.

Many people addicted to drugs spend much longer in recovery facilities and prisons than the 45 days prescribed by Taliban authorities. Radio Azadi, Radio Free Europe’s Afghan arm, reported prison stays of up to six months.

Those who are admitted must sign a pledge to stay off drugs and complete an assessment before their release. If they fail multiple assessments, their time in prison or the recovery facilities can be extended indefinitely.

The United Nations reported that the conditions at Avicenna Hospital – considered the ‘gold standard’ of drug treatment centers in Afghanistan – are “heartbreaking.” International funding has dried up, leaving underpaid, poorly trained staff to deal with patients. Food is scarce, and pharmacy cabinets are practically empty, forcing patients into shock detoxification.

“My children have no one to feed them,” one detainee, held for six months in a Taliban-run rehabilitation program, told the UN.

Afghanistan’s forgotten women addicts

Thousands of women in Kabul with drug addictions face a uniquely harrowing struggle. The women’s drug treatment facility, separated from the men’s and hidden from public view, can house only 150 addicts for 45-day stints.

Overcrowding means that hundreds of women sleep in hallways with barely enough food to survive. Survivors recount prison-like conditions.

Many share similar stories: they became addicted to drugs due to the influence of men or situations where men were the cause.

Mah Gul (a pseudonym), sits upright in her bed, her pale face and frightened eyes telling a story shared by women across Afghanistan.

“I had no idea he was addicted before we got married,” she said, recounting how her husband, unable to afford treatment for her chronic illness, introduced her to opioids to ease her pain. “He gave me poppy, and my pain eased. Whenever I got sick, I used more and more.”

Halima, a 27-year-old mother separated from her husband and children, says she was forced to resort to drugs to endure the separation.

“My husband was addicted and took my children away from me. He went to Iran, leaving me alone with no one,” Halima said. “I became addicted due to the pain of the loss of my children. I searched a lot to find them, but could not.”

The women’s struggles extend beyond addiction, revealing a complex web of substance abuse, domestic violence and societal pressures amid eroding rights under Taliban rule.

“They can’t keep me here for long once my 45 days are completed,” Halima added, her eyes darting nervously. “I am afraid of my husband. I have no place; I don’t have a job. I can’t go from here. What will happen if I stay on the street? I have no home or shelter.”

Women are feeling increasingly isolated under the Taliban with no rights to study or work. Recent edicts ban women’s voices from being heard singing or reading aloud in public, with the regime declaring a woman’s voice “intimate” and forbidden outside the home.

“Women with addiction should not be judged because they are dealing with an illness, with a disorder, that they cannot cure themselves,” said Haibatullah Ebrahimkhil, a psychologist in Kabul. “We should educate them about addiction.”

On Thursday, the Taliban’s Minister of Education extended the ban on women’s education – the only such ban in the world – even further: to speaking about it.

“Just as education for girls is banned,” he said, “questioning it is also banned.”

Taliban celebrates ‘success’ 

Before the Taliban takeover, around 100 drug treatment centres operated across Afghanistan. Today, only 61 remain, according to Taliban government figures. The withdrawal of international aid has left even surviving centres struggling to keep their doors open.

“Public healthcare facilities, especially tertiary hospitals … are struggling to cover essential running costs like staff salaries, medicines and medical supplies, fuel, and oxygen supply,” Médecins Sans Frontières, one of the last international organizations still working in Afghanistan, said in June, noting “the lack of long-term structural support for the health sector in Afghanistan.”

This has not stopped the Taliban regime from celebrating the perceived success of their strict counter-narcotics policies. The regime frequently conducts highly visible — and often violent — raids on addicts’ encampments, presenting these actions as evidence of their commitment to eradicating drug abuse.

In June, the Taliban held an opulent ceremony to mark the ‘Day Against Drug Abuse and Illicit Trafficking’ at Kabul’s Intercontinental Hotel, perched high above the city’s poorest areas where many addicts live.

The Intercontinental, which opened its doors in 1969 as Afghanistan’s first luxury hotel, has been a silent witness to the country’s turbulent history. It has seen seven different governments come and go and has stood through nearly half a century of continuous conflict since 1978.

Once a symbol of Afghanistan’s aspirations for modernity and progress, the hotel is now under Taliban management.

The Intercontinental, Kabul’s largest hotel is perched on the mountains surrounding the city. It has been a symbol of power in Afghanistan’s capital since it opened in 1969.

“Since the establishment of the Islamic Emirate, 54,374 drug addicts have been treated,” Abdul Wali Haqqani, the Taliban’s Deputy Minister of Public Health, declared from the Intercontinental ballroom.

Shams Al-Rahman Minhaj, representing the Ministry of Interior’s Anti-Narcotics Directorate, offered even higher figures: “Since the Islamic Emirate took power, 114,340 drug addicts have been collected and sent to addiction treatment centres. In 2023, 33,226 individuals were collected.”

Talib officials were joined by Jamshid Tanwali, a representative of the World Health Organization (WHO), who spoke on the concerning increase in addiction worldwide.

“In 2011, there were 240 million drug addicts globally; this number rose to 296 million in 2021,” Tanwali said. “Given the global increase, drug use in Afghanistan might also have risen.”

As addiction rates climb, Afghanistan’s opium production has plummeted under Taliban rule. UN figures show poppy cultivation in Afghanistan fell by 95% in 2023. Opium production dropped from 6,200 tons to 333 tons.

Myanmar has overtaken Afghanistan as the world’s largest opium producer, ending Afghanistan’s two-decade dominance of the illicit global market. At its peak in 2007, Afghanistan supplied 93% of the world’s illicit opiates.

Habibullah Aqli, a sociologist, argues that the current approach is insufficient. “There are three basic solutions,” he says, “identifying the main sponsors and drug growers, defining a legal mechanism for drugs and sellers, and developing a policy to address mental aspects of the addicts.”

The decline in opium production comes as the Taliban crackdown on a trade they long profited from. For two decades, the Taliban financed their insurgency through the opium trade, weaving a complex tapestry of economic dependency and addiction throughout Afghan society.

Now in power, the Taliban face the daunting task of dismantling a national crisis they helped create.

Stefan Anderson contributed reporting for this story. 

Image Credits: Jacksoncam, Olaf Kellerhoff.

Flooding is a frequent occurrence in Bangladesh

Japan issued a rare Level 4 evacuation advisory for its southern island, Kyushu, affecting 3.7 million residents as Typhoon Shanshan made landfall on Thursday.

The storm is the strongest to hit the country this year, and has caused widespread power cuts as well as floods. Level 4 is the country’s second-highest alert level.

In Bangladesh, about five million people, including two million children, have been affected by severe monsoon-related flooding this week, according to UNICEF. Bangladesh is one of the countries most vulnerable to climate change because of its extensive coastal exposure and low elevation.

Meanwhile, heavy rains and floods have forced thousands of people out of their homes in west India’s Gujarat state and parts of Pakistan, with a strong typhoon expected to land on Friday.

The Indian government has issued a red warning for extreme rain, thunderstorms and lightning in the eastern part of the state.

In the past 10 days, India’s Tripura state has experienced its highest rainfall since 1983, causing over 2000 mudslides and flooding affecting over 1,7 million people, according to India’s National Emergency Response Centre (NDMI).

Tropical cyclones (typhoons and hurricanes) are fuelled by warm oceans. Scientists estimate that over 90% of the heat caused by human emissions is going into the ocean, heating the sea surface temperatures and intensifying these cyclones.

UN Secretary-General António Guterres (left) meets a community member from Samoa which, like many Small Island Developing States, is already facing severe impacts from sea-level rise.

The extreme weather comes days after UN Secretary-General Antonio Guterres visited Tongo for the Pacific Islands Forum Leaders Meeting, and issued a fresh warning of the dangers of climate change.

“I am in Tonga to issue a global SOS, Save Our Seas, on rising sea levels,” said Guterres, noting that the sea level is rising faster this century than it has in the past 3,000 years.

“A worldwide catastrophe is putting this Pacific paradise in peril. The reason is clear. Greenhouse gases, overwhelmingly generated by burning fossil fuels, are cooking our planet. And the sea is taking the heat, literally,” said Guterres.

A report by the World Meteorological Organisation (WMO) on the State of the Climate in the South-West Pacific 2023 issued to coincide with Guterres’s visit describes how the Pacific Islands are being threatened by “a triple whammy of accelerating sea level rise, ocean warming and acidification”.

Their “socioeconomic viability and indeed their very existence because of climate change”, it warns. 

Marine heatwaves have “approximately doubled in frequency since 1980 and are more intense and are lasting longer,” the report notes.

“Despite accounting for just 0.02% of global emissions – the Pacific islands are uniquely exposed. Their average elevation is just one to two meters above sea level; 90% of the population live within five kilometres of the coast and half the infrastructure is within 500 metres of the sea.”

“Surging seas are coming for us all – together with the devastation of fishing, tourism, and the Blue Economy,” Gueterres warned.

 “Across the world, around a billion people live in coastal areas threatened by our swelling ocean. Yet even though some sea level rise is inevitable, its scale, pace, and impact are not. That depends on our decisions,” said Guterres, reiterating his urgent calls for drastic cuts in greenhouse gas emissions and increasing in climate adaptation.  

Meanwhile, a UN technical brief issued this week notes that sea level rise (SLR) is accelerating as a result of “the melting of land ice and the expansion of seawater as it warms”.

“According to the WMO, the rate of SLR in the past 10 years has more than doubled since the first decade of the satellite record, increasing from 0.21cm per year between 1993–2002 to 0.48cm per year between 2014–2023,” the brief notes.

The recent acceleration in SLR is primarily caused by ice loss in Greenland and Antarctic, which are “losing ice mass at average rates of around 270 and 150 billion tonnes per year, respectively”, with the seven worst years of ice loss occurring in the last decade. 

“At the same time, the ocean has absorbed more than 90% of the excess heat that has accumulated in the earth system since 1971 due to rising greenhouse-gas emissions.

“In 2023, sea-surface temperatures and ocean-heat content reached their highest levels in the observational records. It is expected that the upper 2,000 meters of the ocean will continue to warm due to excess heat that has accumulated in the Earth system from global warming — a change that is irreversible on centennial to millennial timescales,” the brief warns.

Image Credits: UNICEF, Kiara Worth/ UN.

US officials hand over the mpox vaccines to Nigerian health officials

Nigeria, accounting for just 1% of Africa’s confirmed mpox cases, has become the first African country to receive a vaccine shipment outside a clinical trial. 

This week, Nigeria received 10,000 doses of Jynneos, a vaccine manufactured by Bavarian Nordic and donated by the United States government.

“We are pleased to receive this modest initial donation of the mpox vaccine which is safe and efficacious,” Nigeria’s Minister of Health, Muhammad Ali Pate said. “We will continue to strengthen surveillance and be vigilant to prevent and control mpox.”

Leading up to the vaccine delivery, Dr Jean Kaseya, Director-General of the Africa CDC, confirmed that Nigeria was one of the two African countries to have issued regulatory approval for the vaccine’s introduction. 

Nigeria’s preparedness, marked by a robust vaccination plan, ensured its place at the forefront of receiving these doses.

According to Africa CDC’s latest epidemic intelligence report, nearly 21,000 suspected and fewer than 3,400 confirmed mpox cases have been reported across Africa this year. 

While the Democratic Republic of Congo (DRC) accounts for 95% of suspected and 90% of confirmed cases, Nigeria has only confirmed 40 cases and no deaths — a mere 1% of the continent’s total confirmed cases. 

Despite this relatively low number, Nigerian public health officials have raised the alert level and strengthened outbreak preparedness.

‘Very, very busy’

Dr Jide Idris, head of Nigeria’s frontline agency for disease prevention and control, the Nigeria Centre for Disease Control (NCDC), has had action-packed days since mpox was declared a public health emergency of international concern (PHEIC) – for the second time in two years.

The day after the announcement, Idris was too busy for interviews, his schedule crowded with preparations and briefings. 

The atmosphere at the NCDC’s head office was intense, mirroring the urgency felt across the country as teams worked tirelessly to monitor and coordinate response to multiple outbreaks. 

Meanwhile, requests for guidance on Nigeria’s mpox preparedness poured in. Between briefings for the health minister, press briefings and meetings with health commissioners from Nigeria’s 36 states, he found a few moments to speak to Health Policy Watch.

“It is very busy, very busy,” he said. “We do not have Clade 1b in Nigeria. All cases are Clade 2,” Idris said. 

Clade 1b is the new strain that is spreading fast in the DRC and neighbouring countries.

Idris outlined Nigeria’s three-pronged mpox response strategy: enhancing surveillance at ports of entry, boosting laboratory capacity for testing and genomic surveillance, and providing medical countermeasures (MCM) commodities.

Although mpox is currently classified as a PHEIC, the NCDC’s latest situation report for Nigeria shows a stable outlook: no surprises in case counts, no fatalities, and a consistent pattern in states reporting cases. 

There has been no change in cases since 18 August 18, when the cumulative case count for 2024 stood at 40 across 19 states. Only five states reported more than two confirmed cases: Bayelsa (5), Akwa Ibom, Enugu, and Cross River (4 each), and Benue (3).

Bayelsa, which reported the third highest number of confirmed cases (45) during the 2022 outbreak and ranked second the previous year, has consistently been among the top three states for mpox cases in Nigeria over the past eight years, except in 2020.

So far in 2024, children under the age of 10 years account for 35% of confirmed cases, followed by adults aged 31 to 40 years, who make up 20%.

“Before 2024, most of the confirmed cases were in young adults aged 10-40 years, with males being predominantly affected. In 2024, however, over 33% of confirmed cases are in children aged 0-10 years,” Idris told Health Policy Watch.

Beyond Nigeria and beyond vaccines

According to the official announcement, the 10,000 vaccine doses will be administered in a two-dose schedule to 5,000 individuals most at risk of mpox, including close contacts of confirmed cases and frontline healthcare workers. 

The vaccination exercise will primarily target the five states with recorded cases, with provisions for reactive vaccination in other states as needed.

With DRC not getting the first mpox shipment despite its central status in the outbreak, attention is on the global health players’ ability to let priority guide allocation and delivery of doses. 

Gavi CEO Sania Nishtar revealed that, aside from donations from the US government and the vaccine manufacturer, DRC can also access 65,000 doses of mpox vaccine from Gavi immediately after it makes a request to Gavi. 

However, Nishtar noted that the current supply of mpox vaccines will not be enough to reach everyone in Nigeria, the DRC or elsewhere that needs the shots hence the need to also bring attention to other areas, especially in the short term.

“The first response should be to boost areas such as surveillance, data collection, case management and community engagement: these important foundations are critical for helping us to understand and ultimately contain the outbreak,” Nishtar told Health Policy Watch.

Idris agrees. When asked what he thinks has uniquely positioned Nigeria to fully contain the spread of mpox without having to consider travel restrictions, he did not mention vaccine donations or any medical countermeasures. 

Instead, he acknowledged Nigeria’s vast experience in responding to multiple outbreaks including more fatal ones, and the “surge capacity” it has acquired already – capacity for coordinated response mechanisms, genomic sequencing and molecular diagnosis.

This is why Nigeria is one of the very few African countries reporting cases that do not have a wide gap between suspected and confirmed cases.

Image Credits: WHO.

A UNICEF staff member checks a polio vaccination shipment for Gaza’s vaccine campaign. The proliferation of untreated sewage and waste in wartime Gaza has led to the re-emergence of poliovirus.

BREAKING:  A massive polio vaccine campaign targeting some 640,000 Gaza children is now set to begin on Sunday, 1 September, with agreement by Israel for a three-day humanitarian pause in fighting, a senior WHO official said on Thursday. A second round of the campaign for the two dose vaccine is planned three weeks later. 

“We have had discussions with Israeli authorities and we have agreed to humanitarian pauses…for three days,” said WHO’s Dr. Rik Peeperkorn, speaking to reporters at a briefing at UN Headquarters in New York City.  “I am not going to say this is the ideal way forward. But this is a workable way forward…we have to stop [polio] transmission in Gaza and outside Gaza.”

“Of course, all parties will have stick to this. We have to make sure that everyday we can do this campaign in this humanitarian pause…it is an ambitious target of 90%, but the teams here are ready for it, we are ready to go,” said Peeperkorn.
He was referring to the nearly 11-months of Israeli-Hamas fighting that began 7 October with a bloody Hamas incursion into two dozen Israeli communities near the Gaza enclave in which 1200 people, mostly civilians, were killed and 240 people taken hostage. Following that, Israel launched a devastating invasion of Gaza in which some 40,000 Palestinians have died.
Against the backdrop of continued fighting, some 1.2 million polio vaccine doses reached the Gaza Strip on Sunday via Israel’s Kerem Shalom crossing, after arriving at Tel Aviv’s Ben Gurion airport the week before.
Inside Gaza, some 2,700 medical staff have been trained and poised for deployment at 400 vaccination points to ensure doses can be delivered to all eligible recipients in two stages, Palestinian health officials said.
Trucks carrying special refrigeration equipment for vaccine storage and transportation were also brought into the Gaza Strip by the United Nations Children’s Fund (UNICEF) last Friday. 

Distribution complicated by evacuation orders

UN agencies have pressed ahead with a planned polio vaccination campaign against the background of a rash of new Israeli military evacuation orders imposed on displaced Palestinians sheltering in designated “safe zones”.

Tens of thousands of Palestinians have been ordered move once again from parts of the central Gaza city of Deir al Balah as well as sections of Khan Younis in the south. The areas were among those previously designated by the Israeli army as humanitarian zones for the more than 1.2 million Gazans who have been internally displaced during the grinding war between Israel and the Palestinian Hamas.

“Mass evacuation orders are the latest in a long list of unbearable threats to UN and humanitarian personnel,” Under-Secretary-General Gilles Michaud said in a statement on Tuesday. 

“The timing could hardly be worse,” he added, referring to the polio vaccination programme that was about to start. 

Poliovirus was first detected in Gaza in late June by the Global Polio Laboratory Network. The virus was confirmed in six sewage samples from Khan Younis and Deir al Balah, cities in the south and centre of the 365 square kilometer Gaza Strip. 

In mid-August, three suspected polio cases in children were identified, Health Policy Watch reported, followed by the confirmation of one case in a 10-month old infant last week. As nine out of 10 polio cases are generally asymptomatic, the spread of the virus is likely far wider than reported cases. 

In response, WHO, UNICEF and UN Relief and Works Agency for Palestine Refugees (UNRWA) organised a vaccination campaign targeting over 640,000 children.  

Delaying the vaccinations would have serious consequences, Dr Hamid Jafari, the director of the WHO’s polio eradication programme in the Eastern Mediterranean warned on 23 August.

“The risk of this virus spreading into Israel, into the West Bank and into surrounding countries like Lebanon, Syria, Egypt and Jordan is high. So we need to act fast.”

Humanitarian pauses

To reach the intended vaccination target and gain better population immunity, WHO and other UN agencies had appealed for at least two humanitarian pauses of seven days to deliver the vaccine doses.

The pause in the grinding 11 month Israel-Hamas war is necessary to ensure a cold chain of the vaccines, as well as to guarantee the safety of patients reaching healthcare points and the right timing of the second dose, officials have stressed.

The operation in a conflict zone will be complex, and its outcomes will depend on the conditions on the ground, Sam Rose, Senior Deputy Field Director for UNRWA in Gaza stressed in a statement Monday. 

UN agencies and partners “stand ready to vaccinate children, but need a humanitarian pause. We and the rest of the system involved will do our absolute utmost to deliver the campaign,” Rose said, “because without it, the conditions will be much worse sadly.”

Overcrowding

Polio is a highly infectious viral disease largely affecting children younger than five years of age. It spreads between humans by a fecal-oral route or, in the minority of cases, through contaminated water or food.

One in 200 infections causes permanent paralysis and, in 2-10% of the paralysed, death. While there is no known cure for polio, the disease was mostly eradicated in the World Health Assembly-initiated Global Polio Eradication Initiative starting 1988. 

In some cases, the weakened virus present in the oral polio vaccine (OPV) can mutate and spread in communities not fully vaccinated against polio, especially in poor hygienic conditions or in overcrowded areas. The longer it is allowed to circulate, the higher the chance for further mutations, creating concerns about a large-scale outbreak.

Updated 29 August, 2024.  Elaine Ruth Fletcher contributed to reporting on this story. 

Image Credits: UNICEF.

Dr Faustine Ndugulile (centre) flanked by outgoing WHO Africa

Tanzania’s Dr Faustine Ndugulile has been nominated as the next Regional Director for the World Health Organization (WHO) African Region, defeating more experienced WHO insiders in a closely contested race.

Ndugulile secured 25 of the 46 votes at the WHO Africa regional conference in the Republic of Congo, defeating Dr Ibrahima Socé Fall (proposed by Senegal), Dr Richard Mihigo (proposed by Rwanda) and Dr Boureima Hama Sambo (proposed by Niger). 

Socé Fall has a high-profile position at WHO headquarters in Geneva and Mihigo has held global positions in the vaccine alliance, Gavi, and WHO.

Ndugulile, a former deputy health minister and ICT minister in his country, has represented the Kigamboni constituency in Dar Es Salaam as a Member of Parliament since 2010 and chairs the country’s parliamentary health committee.

He is also vice-chair of the global Inter-parliamentary Union’s advisory group on health. 

Aside from a medical degree, 55-year-old Ndugulile has a Masters degree in public health and a law degree. 

While representing Tanzania at the Pan African Parliament from 2015 to 2018, he chaired the Inter-Parliamentary Union (IPU) Advisory Group on Maternal, Child Health, Newborn, and HIV/AIDS from 2015 to 2017. 

In his CV, Ndugulile lists his notable achievements, including “championing the passage of the Universal Health Insurance Bill in 2023, advocating for the implementation of an integrated and coordinated community health worker program and successfully advocating for the ratification of the African Medicine Agency (AMA) convention”.

Describing himself as a “technocrat, politician and policy maker”, Ndugulile has promised to I “prioritize strengthening of WHO country offices to ensure timely, relevant, optimal and effective support to the member states”.

His nomination will be submitted to the WHO Executive Board meeting in January 2025, and he is expected to take office in February 2025 for a five-year term.

Ndugulile will succeed Botswana’s Dr Matshidiso Moeti, who has served two five-year terms at the helm.

“Dr Ndugulile has earned the confidence and trust of the Member States of the region to be elected the next regional director for WHO Africa. This is a great privilege, and a very great responsibility,” said WHO Director General Dr Tedros Adhanom Ghebreyesus. 

“I and the entire WHO family in Africa and around the world will support you every step of the way.”

Tedros also thanked Moeti “for the example she has set, and the legacy she has left”.

Moeti congratulated Ndugulile, describing the position as “extremely fulfilling”. 

“Despite the many challenges, I know you will take the baton and go on to accelerate the gains already made, putting the health and well-being of the people of Africa at the centre,” said Moeti.

The 50 cities evaluated in the City Heartbeat Index.

Hong Kong and London topped the list of 50 cities ranked for their efforts to prevent and address cardiovascular diseases – while Kathmandu and Cairo languished at the bottom.

The City Heartbeat Index is a first-of-its-kind initiative of the World Heart Federation (WHF), a Geneva-based non-profit that works on cardiovascular disease (CVD) prevention.

CVD is one of the top causes of death worldwide, according to the World Health Organization (WHO).

Preventing them could significantly improve public health and quality of life for the population living in a city.

The index evaluated cities using 44 indicators including social determinants of health such as poverty, environmental factors such as air quality, and health risks like hypertension, access to health services and health policies.

It used data from city government websites, health departments and published literature, along with interviews with local experts to validate findings and fill information gaps.

“This is the first attempt of this kind, and more importantly that it is going to enthuse the governments or the non-governmental organizations or the local bodies to be trying to do better,” said Dr Jagat Narula, president-elect of the WHF. “We are talking about the heartbeat index here, but it is actually going to give you a much broader vision and much better chances of working towards policies.”

While there were a few exceptions, cities in Asia and Africa performed the worst. Even high-income cities such as Riyadh and Kuwait City ranked poorly.

Hong Kong and London topped the list of the City Heartbeat Index.

“I am extremely proud of the work we have done to make London a healthier place to live. We have made real progress improving health outcomes by taking old polluting cars off our roads and bringing cleaner air to millions more Londoners, enabling more walking and cycling and promoting healthier food advertising on our transport network,” said London mayor Sadiq Khan.

The burden of CVD is driving action

Of the 10 highest scoring cities on the Index, four (Berlin, Toronto, Helsinki and New York City) are in countries with high burden of CVD.

Access to universal healthcare has also helped cities’ ranking.

“It is the factors of what is the will, how much is the advocacy, how the policy has resulted in all those things, whether there is a universal care. Or the National Health schemes, for example, in London and Madrid and other places where the healthcare is available to all,” Narula told Health Policy Watch.

Some cities in middle-income countries like Sao Paulo in Brazil and Bogota in Colombia have also done well, said Narula, emphasizing that resources are not a constraint when there is will.

Critical data is still missing

However, critical data is missing to evaluate cities. Few cities have data on food security (42%), cholesterol (22%) or transfat consumption (14%) – key risk factors for CVD.

This data would provide the first step in understanding the scale and scope of how key risk factors are affecting populations.

Only Jakarta and Singapore had data available for all 12 sub-indicators included in the Index, demonstrating intent to understand and address the factors affecting cardiovascular health.

Percentage of cities for which data are available on key factors impacting CVD risk

Cities prioritise some risk factors over others

Based on the average scores across the key CVD risk factors, cities most often prioritise diabetes (78.9), tobacco use (66.5), hypertension (63.0) and obesity (62.9).

High scores on these indicators are due to the presence of city-level data.

Other key risk factors, including levels of consumption of vegetables (45.8) and trans fats (53.9), and levels of physical activity (60.4) and cholesterol (31.8), have lower scores, which may indicate fewer city-level efforts to monitor and address these health concerns.

“The City Heartbeat Index shows that the many efforts by cities – where over half of the world’s population resides – on heart health are visible and increasingly important,” said Dr Vasilisa Sazonov at Novartis who sponsored the index.

“There are opportunities to improve data collection at the city level including prioritising CVD risk factors that have typically been overlooked such as high cholesterol,” said Sazonov.

Worsening climate impacts like heat were not a part of the report this year but Narula said that the indicators will evolve.

Image Credits: City Heartbeat Index Report.

Children are vulnerable to mpox due to contact with infected animals and poor immune systems.

The government of Japan is preparing to send donations of mpox vaccines to the Democratic Republic of Congo (DRC), the epicentre of the global outbreak, according to the Africa Centre for Disease Control and Prevention (Africa CDC).

The Japan-based KM Biologics makes LC16, the only mpox vaccine currently licensed for children. This is essential for Africa up to 60% of cases in the DRC and 43% in neighbouring Burundi are children under 10.

Most of the children infected in the eastern DRC are malnourished, which means that their immune systems are weak and susceptible to mpox infection.

Vaccine donations are also underway from the European Union (215,000 doses), the US (15,000) and Gavi (5,000), and the first vaccines expected to land on the continent next week, Africa CDC Director-General Dr Jean Kaseya told a media briefing on Tuesday. 

Bavarian Nordic’s Jynneos (also called MVA-BN), is the other vaccine expected. This is not yet licensed for use in children but the company said it had recently submitted clinical data to the European Medicines Agency “to potentially support the use of the mpox vaccine in adolescents (12–17-year-olds)”. 

This follows a clinical study involving over 300 adolescents completed with the US National Institute of Allergy and Infectious Diseases (NIAID).

“Furthermore, through a collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI), the company will shortly initiate a clinical trial to assess the immunogenicity and safety of MVA-BN in children from 2-12 years of age, aiming to further extend the indication of the vaccine into younger populations,” the company added.

Bavarian Nordic confirmed that it was working on tech transfer to enable African manufacturers to make the vaccine, which Kaseya told the briefing would involve the end process of “fit and finish”.

The African Union has made $10 million available to address the outbreak, and this is being used to prepare countries to receive and distribute the vaccines and improve surveillance, said Kaseya.

Gabon reports first case

Meanwhile, Gabon is the latest country to report an mpox case as cases continue to rise on the continent – up almost 2000 to 22,863 cases since last week.

However, Kaseya said that the Africa CDC was concerned that this was an undercount given weaknesses in surveillance, with some countries only able to test around 18% of suspected cases.

To address this, Africa CDC is deploying 72 epidemiologists to the outbreak hotspots to enhance surveillance and data quality.

Kaseya also confirmed that the Africa CDC had met close to 200 partners to galvanise support for mpox response, and had been assured via a foreign ministers’ forum that Western countries would not impose a travel ban on people from outbreak areas.

Kaseya also said that Gavi and UNICEF had been given the go-ahead from the World Health Organization (WHO) to procure vaccines for the continent even though the outcome of the WHO’s emergency use listing (EUL) of the two mpox vaccines was only expected in mid-September.

The EUL procedure fast-tracks unlicensed medical products in public health emergencies. As the vaccines are already licensed in the US and European Union so the EUL is likely to be issued.

The WHO has been criticised for being too slow to evaluate potential mpox vaccines already approved by the US and Europe, thus leaving Africa dependent on donated vaccines.

“Currently, we are putting all African countries’ efforts in one basket. This is why we say we are finalizing the response plan, and we have a meeting in September where countries will also pledge funding [for the outbreak],” said Kaseya.

Image Credits: Tessa Davis/Twitter .